BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Relatlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Relatlimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06712927-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06712927)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Trial of Relatlimab\, 
 Nivolumab\, and Ipilimumab in Patients With Asymptomatic and Symptomatic M
 elanoma Brain Metastases\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/relatlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06712927
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03610711-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relatlimab: Phase 1/2 readout est. (NCT03610711)
DESCRIPTION:Relatlimab\, phase 1/2.\nStudy: REACTION (Radiation Enhanced As
 sessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivol
 umab in Combination With Other Immuno-oncology (IO) Agents After Targeted 
 Systemic Radiation in Patients With Advanced Esophagogastric Cancer\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03610711
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04204837-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relatlimab: Phase 2 readout est. (NCT04204837)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Nivolumab for Treatment of Squamo
 us Cell Carcinoma of the Skin\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/relatlimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04204837
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151236-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06151236)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Neoadjuvant Nivolumab and Relatli
 mab in Merkel Cell Carcinoma\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/relatlimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06151236
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06237920-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06237920)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Stage II-IIIa Urothelial Cancer R
 andomizing Pre-operative Nivolumab With or Without Relatlimab\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06237920
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04953104-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relatlimab: Phase 2 readout est. (NCT04953104)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: ARID1A and/or KDM6A Mutation and 
 CXCL13 Expression\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/relatlimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04953104
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05176483-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Relatlimab: Phase 1 readout est. (NCT05176483)
DESCRIPTION:Relatlimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in 
 Participants With Solid Tumors\nEstimated primary completion: 31 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/relatlimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05176483
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03044613-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Relatlimab: Phase 1 readout est. (NCT03044613)
DESCRIPTION:Relatlimab\, phase 1.\nStudy: Nivolumab +/- Relatlimab Prior to
  Chemoradiation With II/III Gastro/Esophageal Cancer\nEstimated primary co
 mpletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03044613
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912244-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05912244)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: A Study of IO102/IO103
 \, Nivolumab\, and Relatlimab in People With Melanoma\nEstimated primary c
 ompletion: 9 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05912244
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034536-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05034536)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: PD-1 Antibody Therapy 
 + Infliximab for Metastatic Melanoma\nEstimated primary completion: 30 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/relatlimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT050345
 36
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03521830-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Relatlimab: Phase 2 readout est. (NCT03521830)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Nivolumab Alone or Plus Relatlima
 b or Ipilimumab for Patients With Locally-Advanced Unresectable or Metasta
 tic Basal Cell Carcinoma\nEstimated primary completion: July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/relatlimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03521830
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347212-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05347212)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Phase II Trial of Immunotherapy i
 n Patients With Carcinomas Arising From the Renal Medulla\nEstimated prima
 ry completion: 16 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05347212
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04697576-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Relatlimab: Phase 1 readout est. (NCT04697576)
DESCRIPTION:Relatlimab\, phase 1\, Melanoma.\nStudy: Intralesional Influenz
 a Vaccine for the Treatment of Stage I-IV Melanoma\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04697576
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03607890-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Relatlimab: Phase 2 readout est. (NCT03607890)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Study of Nivolumab and Relatlimab
  in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 
 Inhibitor\nEstimated primary completion: October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/relatlimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03607890
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Relatlimab: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999980-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06999980)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Neo IRENIE (NEOadjuvan
 t Ipilimumab\, RElatlimab\, NIvolumab Evaluation)\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 latlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06999980
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428007-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05428007)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Interleukin-6 Receptor
  Inhibitor Sarilumab in Combination With Ipilimumab\, Nivolumab and Relatl
 imab in Patients With Unresectable Stage III or Stage IV Melanoma\nEstimat
 ed primary completion: 17 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05428007
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624475-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06624475)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Neoadjuvant Nivolumab + Relatlima
 b (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinom
 a\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06624475
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704647-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Relatlimab: Phase 2 readout est. (NCT05704647)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Phase II Study of Nivo
 lumab in Combination With Relatlimab in Patients With Active Melanoma Brai
 n Metastases\nEstimated primary completion: 31 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/relatlimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05704647
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295159-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06295159)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: Neoadjuvant and Adjuva
 nt Anti-PD1 or Combinations for Locoregionally Advanced Melanoma\nEstimate
 d primary completion: November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06295159
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06708949-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06708949)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: A Randomized Phase 2 Trial of Niv
 olumab\, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First
 -line Advanced Renal Cell Carcinoma (RCC)\nEstimated primary completion: 1
 5 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rela
 tlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06708949
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06029270-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06029270)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Testing the Addition of BMS-98601
 6 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recu
 rrent or Metastatic Nasopharyngeal Cancer\nEstimated primary completion: 3
 0 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/relatli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06029270
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504796-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Relatlimab: Phase 2 readout est. (NCT07504796)
DESCRIPTION:Relatlimab\, phase 2\, Melanoma.\nStudy: ctDNA-guided Addition 
 of Ipilimumab to Patients Receiving Nivolumab and Relatlimab\nEstimated pr
 imary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07504796
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459543-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20290526
DTEND;VALUE=DATE:20290527
SUMMARY:Relatlimab: Phase 4 readout est. (NCT07459543)
DESCRIPTION:Relatlimab\, phase 4\, Melanoma.\nStudy: A Study to Assess the 
 Safety\, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination
  (FDC) In Unresectable or Metastatic Melanoma Participants In India\nEstim
 ated primary completion: 26 May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07459543
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06816927-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06816927)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Trial of Glioblastoma Immunothera
 py Advancement With Nivolumab and Relatlimab\nEstimated primary completion
 : 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/relatl
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06816927
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Relatlimab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstimat
 ed primary completion: 25 August 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Relatlimab: Phase 3 readout est. (NCT06561386)
DESCRIPTION:Relatlimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy 
 vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non
 -small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated primary co
 mpletion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06561386
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683755-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20300816
DTEND;VALUE=DATE:20300817
SUMMARY:Relatlimab: Phase 1/2 readout est. (NCT06683755)
DESCRIPTION:Relatlimab\, phase 1/2\, Melanoma.\nStudy: Phase I/IIa Dose Fin
 ding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in Fi
 rst Line Therapy of Metastatic Melanoma (TRINITY)\nEstimated primary compl
 etion: 16 August 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06683755
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987241-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Relatlimab: Phase 2/3 readout est. (NCT05987241)
DESCRIPTION:Relatlimab\, phase 2/3.\nStudy: Testing the Role of DNA Release
 d From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy Afte
 r Surgical Removal of the Bladder\, Kidney\, Ureter\, and Urethra for Urot
 helial Cancer Treatment\, MODERN Study\nEstimated primary completion: 2 Se
 ptember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/relatli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05987241
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963905-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Relatlimab: Phase 1/2 readout est. (NCT06963905)
DESCRIPTION:Relatlimab\, phase 1/2.\nStudy: Saci Nivo Rela for TNBC\nEstima
 ted primary completion: December 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06963905
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281924-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Relatlimab: Phase 1/2 readout est. (NCT07281924)
DESCRIPTION:Relatlimab\, phase 1/2\, Melanoma.\nStudy: Hepzato Kit and Opdu
 alag for Metastatic Melanoma and Liver Metastasis\nEstimated primary compl
 etion: December 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07281924
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06715241-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Relatlimab: Phase 2 readout est. (NCT06715241)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: A MULTICENTER\, SEEKING SIGNAL\, 
 RANDOMISED\, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB 
 ALONE IN LOCALLY ADVANCED CERVICAL CANCERS\nEstimated primary completion: 
 31 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rel
 atlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06715241
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03026140-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20320301
DTEND;VALUE=DATE:20320302
SUMMARY:Relatlimab: Phase 2 readout est. (NCT03026140)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Neoadjuvant Immune Checkpoint Inh
 ibition and Novel IO Combinations in Early-stage Colon Cancer\nEstimated p
 rimary completion: 1 March 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/relatlimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03026140
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644312-2059@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Relatlimab: Phase 2 readout est. (NCT07644312)
DESCRIPTION:Relatlimab\, phase 2.\nStudy: Study of Relatlimab and Nivolumab
  (Opdualag) in Replication Repair Deficient HGG and DIPG\nEstimated primar
 y completion: 1 March 2033. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07644312
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
